Guangdong Zhongsheng Pharmaceutical Co., Ltd. Stock: price and insider trades · China
众生药业
No insider purchase over the last 90 days. The latest, by 陈永红, was filed 26 Apr 2024.
Guangdong Zhongsheng Pharmaceutical Co., Ltd.: what insiders have been doing
Guangdong Zhongsheng Pharmaceutical Co., Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SSE / SZSE (CSRC). Guangdong Zhongsheng Pharmaceutical Co., Ltd. has had no insider filing for more than a year; the last one goes back to 26 April 2024.
Our records for Guangdong Zhongsheng Pharmaceutical Co., Ltd. go back to 2023, with 2 purchases and 1 sale on the open market in total.
For comparison within the same sector, see the insider buying recorded at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by SSE / SZSE (CSRC) and describes the past, not future prices; it is not investment advice.
Since the insiders bought
- -26.6%Entry CN¥15.24 · Close at T+365 CN¥11.19
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 42,800 shares54.8% of flowA股XSHESZSE:173000007573328700Canonical exit: 25 Jul 2024 (T+90)
- 35,600 shares45.2% of flowA股XSHESZSE:173000007554064640Canonical exit: 24 Jul 2024 (T+90)
- 1,200 shares100.0% of flowA股XSHESZSE:173000006601860640
3 of 3 declarations
About Guangdong Zhongsheng Pharmaceutical Co., Ltd.
众生药业 is a company operating in the health and pharmaceutical sector, listed on the XSHE market. It focuses on the research, development, and production of innovative medications.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
